Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Total Voting Rights

31 Oct 2023 10:40

RNS Number : 8777R
Dechra Pharmaceuticals PLC
31 October 2023

31 October 2023

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

LEI: 213800J4UVB5OWG8VX82

Total Voting Rights

In conformity with DTR 5.6.1R, the Company notifies the market of the following:

As at the date of this announcement, the Company's issued share capital consists of 113,891,571 ordinary shares with a nominal value of 1 pence each (Ordinary Shares), with voting rights. The Company does not hold any Ordinary Shares in Treasury.

Therefore, the total number of Ordinary Shares with voting rights is 113,891,571.

The above figure of 113,891,571 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Dechra Pharmaceuticals PLC

Telephone number: +44 (0) 1606 814730

Email: corporate.enquiries@dechra.com

About Dechra

Dechra is a global veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVREAEEFDDLDFFA
Date   Source Headline
23rd Nov 202310:05 amRNSForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
23rd Nov 202310:04 amRNSForm 8.5 (EPT/RI)
23rd Nov 20239:55 amPRNForm 8.3 - Dechra Pharmaceuticals Plc
23rd Nov 20239:25 amRNSForm 8.3 - Dechra Pharmaceuticals plc
23rd Nov 20238:33 amRNSHolding(s) in Company
23rd Nov 20237:28 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
23rd Nov 20237:00 amRNSForm 8.3 - Dechra Pharmaceuticals plc
22nd Nov 20234:32 pmRNSForm 8 (DD) Dechra Pharmaceuticals Plc
22nd Nov 20233:30 pmRNSForm 8.3 - DPH LN
22nd Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
22nd Nov 20233:20 pmPRNForm 8.3 - Dechra Pharmaceuticals PLC
22nd Nov 20233:02 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
22nd Nov 20232:58 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
22nd Nov 20232:50 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
22nd Nov 20232:45 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
22nd Nov 20232:04 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
22nd Nov 20231:20 pmPRNForm 8.3 - Dechra Pharmaceuticals PLC
22nd Nov 202311:23 amRNSForm 8.3 - Dechra Pharmaceuticals plc
22nd Nov 202310:13 amRNSForm 8.5 (EPT/RI)
22nd Nov 202310:12 amRNSForm 8.5 (EPT/NON-RI)
22nd Nov 20239:54 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
22nd Nov 20239:38 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
22nd Nov 20239:30 amRNSForm 8.3 - Dechra Pharmaceuticals plc
22nd Nov 20239:23 amRNSHolding(s) in Company
22nd Nov 20237:29 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
21st Nov 20235:01 pmRNSRule 2.9 Announcement
21st Nov 20233:30 pmRNSForm 8.3 - DPH LN
21st Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
21st Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
21st Nov 20233:08 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
21st Nov 20232:48 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
21st Nov 20231:36 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
21st Nov 20231:05 pmPRNForm 8.3 - Dechra Pharmaceuticals Plc
21st Nov 202312:44 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
21st Nov 202311:16 amRNSForm 8.3 - Dechra Pharmaceuticals plc
21st Nov 202310:50 amRNSForm 8.3 - Dechra Pharmaceuticals plc
21st Nov 202310:42 amRNSForm 8.5 (EPT/RI)
21st Nov 202310:41 amRNSForm 8.5 (EPT/NON-RI)
21st Nov 202310:41 amRNSForm 8.3 - Dechra Pharmaceuticals Plc
21st Nov 202310:07 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
21st Nov 20239:39 amRNSForm 8.3 - Dechra Pharmaceuticals plc
21st Nov 20239:18 amRNSHolding(s) in Company
21st Nov 20238:30 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
21st Nov 20237:10 amRNSHolding(s) in Company
21st Nov 20237:09 amRNSHolding(s) in Company
21st Nov 20237:00 amRNSForm 8.3 - Dechra Pharmaceuticals, Plc
20th Nov 20235:08 pmRNSRule 2.9 Announcement
20th Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
20th Nov 20233:05 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
20th Nov 20232:50 pmPRNForm 8.3 - Dechra Pharmaceuticals PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.